Stockscreener 앱 받기
2.28
8.57%
0.18
시간 외 거래:
2.30
0.02
+0.88%
전일 마감가:
$2.10
열려 있는:
$2.12
하루 거래량:
4.74M
Relative Volume:
1.83
시가총액:
$376.00M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-114.00
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
+11.76%
1개월 성능:
-3.80%
6개월 성능:
+270.61%
1년 성능:
+93.22%
1일 변동 폭
$2.07
$2.29
1주일 범위
$2.00
$2.29
52주 변동 폭
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.28 | 346.32M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
How to recover losses in CytomX Therapeutics Inc. stockWeekly Trend Summary & Verified Momentum Stock Ideas - Newser
CytomX Therapeutics Inc. Building a Base Near Support2025 Buyback Activity & Entry Point Strategy Guides - beatles.ru
Is CytomX Therapeutics Inc. forming higher highs and higher lowsBear Alert & Short-Term Swing Trade Alerts - خودرو بانک
Will CytomX Therapeutics Inc. benefit from AI trendsPortfolio Risk Summary & Free Expert Approved Momentum Trade Ideas - خودرو بانک
Can CytomX Therapeutics Inc. maintain sales growthJuly 2025 Market Mood & Technical Buy Zone Confirmation - خودرو بانک
Identifying reversal signals in CytomX Therapeutics Inc.2025 Historical Comparison & Risk Controlled Daily Plans - Newser
News impact scoring models applied to CytomX Therapeutics Inc.July 2025 Spike Watch & Expert Approved Momentum Trade Ideas - Newser
How to forecast CytomX Therapeutics Inc. trends using time seriesJuly 2025 Gainers & Community Supported Trade Ideas - Newser
Should you hold or exit CytomX Therapeutics Inc. nowTrade Risk Assessment & Reliable Price Action Trade Plans - Newser
Historical volatility pattern of CytomX Therapeutics Inc. visualizedMarket Growth Summary & Free High Accuracy Swing Entry Alerts - Newser
Statistical indicators supporting CytomX Therapeutics Inc.’s strengthWeekly Loss Report & Consistent Return Strategy Ideas - Newser
Can you recover from losses in CytomX Therapeutics Inc.Market Movement Recap & Fast Entry Momentum Alerts - Newser
Is CytomX Therapeutics Inc. vulnerable to short sellersQuarterly Investment Review & Safe Capital Allocation Plans - خودرو بانک
Sentiment analysis tools applied to CytomX Therapeutics Inc.Quarterly Portfolio Report & Consistent Return Strategy Ideas - Newser
CytomX Therapeutics Inc. stock trend forecast2025 Macro Impact & AI Forecasted Stock Moves - Newser
Will CytomX Therapeutics Inc. stock recover after recent dropInsider Selling & Weekly Chart Analysis and Guides - Newser
CytomX Therapeutics Inc.’s volatility index tracking explainedGold Moves & Smart Swing Trading Techniques - Newser
Real time social sentiment graph for CytomX Therapeutics Inc.July 2025 Movers & High Accuracy Swing Entry Alerts - Newser
Technical analysis overview for CytomX Therapeutics Inc. stock2025 Bull vs Bear & Momentum Based Trading Signals - Newser
Is CytomX Therapeutics Inc. stock bottoming outJuly 2025 Trends & Fast Gaining Stock Strategy Reports - Newser
What institutional flow reveals about CytomX Therapeutics Inc.Market Performance Recap & Real-Time Sentiment Analysis - Newser
Is CytomX Therapeutics Inc. showing signs of accumulationJuly 2025 PreEarnings & Accurate Intraday Trade Tips - Newser
Will CytomX Therapeutics Inc. benefit from macro trends2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
CytomX Therapeutics Inc. stock trendline breakdownJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - Newser
Leading vs lagging indicators on CytomX Therapeutics Inc. performanceMarket Growth Review & Accurate Technical Buy Alerts - Newser
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
Published on: 2025-09-03 09:30:47 - Newser
What earnings revisions data tells us about CytomX Therapeutics Inc.Weekly Stock Recap & Long-Term Growth Plans - Newser
Published on: 2025-09-03 13:30:24 - beatles.ru
What earnings revisions data tells us about CytomX Therapeutics IncJuly 2025 Levels & Weekly Momentum Stock Picks - Newser
Is CytomX Therapeutics Inc. benefiting from innovation trendsJuly 2025 Drop Watch & Fast Entry High Yield Tips - خودرو بانک
Will Windtree Therapeutics Inc. outperform during market ralliesJuly 2025 Short Interest & Fast Moving Trade Plans - خودرو بانک
Market Outlook: Will CytomX Therapeutics Inc. benefit from AI trendsJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - خودرو بانک
Is CytomX Therapeutics Inc. trading at a discountJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - خودرو بانک
Will CytomX Therapeutics Inc. bounce back from current supportPortfolio Risk Report & Safe Entry Trade Signal Reports - Newser
Does CytomX Therapeutics Inc. meet Warren Buffett’s criteriaJuly 2025 Momentum & Long-Term Growth Portfolio Plans - خودرو بانک
Volume Summary: Will CytomX Therapeutics Inc. benefit from AI trendsLong Setup & AI Forecasted Entry and Exit Points - خودرو بانک
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytomx Therapeutics Inc 주식 (CTMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
| Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
| McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
| McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
| McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
| Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
| Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
| ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
1.40%
자본화:
|
볼륨(24시간):